Announcement on Using Partial Idle Raised Funds for Cash Management and Redemption
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Using Partial Idle Raised Funds for Cash Management and Redemption
Filed with SSE ·
On 6ix: 6ix.com/news/announcement-on-using-partial-idle-raised-funds-for-cash-management-and-redemption-1
6ix hasn’t read this filing yet.
Beijing Konruns Pharmaceutical Co., Ltd. on 6ix
Earlier from Beijing Konruns Pharmaceutical
- Earnings Preannouncement for 2025
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
- Announcement on Election of Employee Director
- Announcement on FDA Approval for Clinical Trials of KC1086 Project
- Announcement on Company Re-certified as High-tech Enterprise
Later from Beijing Konruns Pharmaceutical
- Announcement on the Receipt of Clinical Trial Notification for KC1036 Combined with PD-1/PD-L1 Antibody in the Treatment of Advanced Solid Tumors
- Announcement on KC1036 Obtaining CDE Approval for Pivotal Phase III Clinical Study in Advanced Thymic Carcinoma
- Announcement on Canceling Special Accounts for Partial Raised Funds and Special Settlement Accounts for Cash Management
- Announcement on Approval by CDE for the Key Phase III Clinical Study of KC1036 as a Second-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
- Announcement on the Implementation of Directors’ and Senior Management Members’ Remuneration in 2025 and the Plan for 2026
Follow Beijing Konruns Pharmaceutical into a list and get an email when it puts out news.
Follow Beijing Konruns Pharmaceutical